Vaderis Announces Acceptance of Abstract on VAD044 Proof-of-Concept Clinical Trial

Basel, Switzerland. November 5th, 2024 Basel, Switzerland. November 5th, 2024 – Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announces an abstract on its medicinal drug candidate VAD044 has been accepted for oral presentation at the 66th ASH Annual Meeting and Exposition taking place December 7-10, 2024, in San Diego, California. A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT) Sunday December 8, 2024, 12 pm Dr. Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology / Oncology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School Session: 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes The abstract is available online at the 66th ASH Annual Meeting and Exposition . Home Medical Need Our Science Our Program Our Team News Home Medical Need Our Science Our Program Our Team News © 2026 Vaderis Therapeutics. Vaderis™ is a trademark of Vaderis Therapeutics AG in the United States, European Union, and Switzerland. Social Privacy Statement Contact Terms of Use Switzerland Building WSJ-350 Lichtstrasse 35 CH-4056 Basel +41 61 563 34 40 USA 250 Parkway Drive Suite 360 Lincolnshire, IL 60069 +1 844 823 3747 Home Medical Need Our Science Our Program Our Team News Home Medical Need Our Science Our Program Our Team News Social Privacy Statement Contact Terms of Use USA 250 Parkway Drive Suite 360 Lincolnshire, IL 60069 +1 844 823 3747 Switzerland Building WSJ-350 Lichtstrasse 35 CH-4056 Basel +41 61 563 34 40 © 2026 Vaderis Therapeutics. Vaderis™ is a trademark of Vaderis Therapeutics AG in the United States, European Union, and Switzerland.

The release as fetched from its publisher. vaderis.com ↗